Last edition
News about
Piramal Pharma Solutions Expands ADC Capabilities with Ajinomoto Bio-Pharma Services Pact
Piramal Pharma Solutions partners with Ajinomoto Bio-Pharma Services to accelerate ADC development and manufacturing, enabling access to AJICAP technology.
Mabwell Signs Malaysia Deal for Denosumab Biosimilars
Mabwell signs a Malaysia licensing deal for denosumab biosimilars, with its partner leading registration and commercialisation while Mabwell handles development, production and supply, strengthening its Asia market expansion strategy.
Merck receives European Commission approval for ENFLONSIA (clesrovimab), a novel RSV preventive therapy for infants, designed to protect against lower respiratory tract disease during their first RSV season.
Lupin Subsidiary Settles US Antitrust Case with Humana
Lupin subsidiary Lupin Pharmaceuticals Inc has reached a USD 30 million settlement with Humana in a US antitrust case, resolving claims without any admission of liability.
Alembic Pharmaceuticals Gets US FDA Nod for Methotrexate Injection
Alembic Pharmaceuticals secures USFDA approval for Methotrexate Injection USP in multi-dose and single-dose vials, a key folate analog metabolic inhibitor used in the treatment of various neoplastic diseases.
UK Accelerates Clinical Trials, Slashing Set-Up Time to Boost Patient Access
Government-backed reforms and Euro 137 million investment cut trial start times significantly, enabling faster access to innovative treatments through the National Health Service.
Interna Therapeutics and Daiichi Sankyo Partner to Advance MNM-Based Targeted Delivery Technology
Interna Therapeutics and Daiichi Sankyo collaborate to advance MNM-based targeted delivery technologies, aiming to enhance intracellular delivery, boost therapeutic activity, and improve performance across key drug development programs.
NHS Speeds Up Clinical Trials, Accelerating Patient Access to New Treatments
The Government-backed reforms and Euro 137 million investment cut trial set-up times, strengthening the UK’s position as a global leader in clinical research and innovation.
Global Study Identifies Most Effective Strategies to Increase Vaccine Uptake
Research in The BMJ finds that expanded access, community engagement, and financial incentives significantly improve vaccination rates across age groups and underserved populations.
Mabwell Strengthens China Pipeline with NMPA Acceptance for Denosumab
Mabwell announces NMPA acceptance of its sBLA for MAIWEIJIAN (denosumab), China’s first approved 120mg denosumab biosimilar, used to treat giant cell tumor of bone in adults and adolescents.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy